Kenvue Inc. closed 13.19% below its 52-week high of $25.17, which the company achieved on May 8th.

Aid, Listerine, Neutrogena, and Johnson's consumer products, reported disappointing Q2 sales and just announced that its CEO ...

Experts are raising concerns about Benadryl’s ability to cross the blood-brain barrier and potential lasting impacts.

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Skillman, New Jersey-based Kenvue Inc. (KVUE) operates as a global consumer health company. Valued at $41.9 billion by market ...

If you look at the history of the S&P 500 ( ^GSPC -0.40%) index, dividend stocks have played a significant role in ...

Kenvue Inc. has announced a leadership change and the initiation of a strategic review aimed at optimizing its brand portfolio and operating model. Kirk Perry, a Kenvue board member and former ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $23.58, a high estimate of $25.00, ...

The stock's fall snapped a four-day winning streak.

We recently published 10 Stocks Jim Cramer Discussed As He Commented On Latest Tariffs. Kenvue Inc. (NYSE:KVUE) is one of the ...

With activist investor Starboard Value holding a seat on Kenvue’s board of directors, the consumer healthcare company is ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...